Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ecopipam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Food-effect Study of Ecopipam Pharmacokinetics
Details : Ecopipam is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 01, 2024
Lead Product(s) : Ecopipam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itraconazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Syneos Health | Cambridge Cognition
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 08, 2024
Lead Product(s) : Itraconazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Syneos Health | Cambridge Cognition
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ecopipam Hydrochloride, a novel investigational compound that is being studied as a potential treatment for Tourette Syndrome, by blocking the action of the neurotransmitter dopamine at the D1 receptor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2023
Details : Ecopipam is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tourette Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : Ecopipam HCl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : PPD | Bioclinica
Deal Size : Inapplicable
Deal Type : Inapplicable
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization
Details : Ecopipam HCl is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Long QT Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 03, 2023
Lead Product(s) : Ecopipam HCl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : PPD | Bioclinica
Deal Size : Inapplicable
Deal Type : Inapplicable
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
Details : Ecopipam hydrochloride is a first-in-class dopamine-1 receptor antagonist which blocks the actions of the neurotransmitter dopamine at the D1 receptor. It is currently approved to treat tourette syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2023
Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
Details : Ecopipam Hydrochloride, a novel investigational compound that is being studied as a potential treatment for certain central nervous system disorders, by blocking the action of the neurotransmitter dopamine at the D1 receptor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 11, 2023
Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
Details : Ecopipam HCl is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Tourette Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Ecopipam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Icon Plc | Nuventra
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ecopipam is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Ecopipam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Icon Plc | Nuventra
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ecopipam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : University of California
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study is evaluating ecopipam, an investigational first-in-class drug, to determine whether it may help improve the ability to get words out without stuttering.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2021
Lead Product(s) : Ecopipam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : University of California
Deal Size : Inapplicable
Deal Type : Inapplicable